Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients-Reference-Cited by-同舟云学术

Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients

Published:2023-12 Issue:6 Volume:8 Page:102043
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Wekking D.^ORCID,Porcu M.^ORCID,Pellegrino B.,Lai E.^ORCID,Mura G.,Denaro N.,Saba L.,Musolino A.^ORCID,Scartozzi M.,Solinas C.^ORCID

Funder

Eli Lilly and Company

European Society for Medical Oncology

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference41 articles.

1. Breast cancer statistics, 2022;Giaquinto;CA Cancer J Clin,2022

2. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study;Tamura;Lancet Oncol,2019

3. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer;Modi;N Engl J Med,2020

4. Enhertu 100 mg Powder for Concentrate for Solution for Infusion: EU Summary of Product Characteristics,2023

5. US food and drug administration approval summary: fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer;Narayan;J Clin Oncol,2023

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China;Cancer;2024-08-02

2. The radiologist’s role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review;Insights into Imaging;2024-08-01

3. Pharmacogenomics: A Genetic Approach to Drug Development and Therapy;Pharmaceuticals;2024-07-13

4. Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms;Blood;2024-07-11

5. Trastuzumab deruxtecan in breast cancer;Critical Reviews in Oncology/Hematology;2024-06